The CDC recommends that immunocompromised people age 65 and older should get a second dose of the 2024-2025 COVID vaccine.

Immunocompromised adults or those who are older than 65 should get a second dose of the latest COVID-19 vaccine, the Centers ...

The U.S. Food and Drug Administration has asked a federal judge in Texas to throw out a public records lawsuit related to ...

Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.

The campaign “caused Americans to lose trust in the public health system,” House Energy and Commerce Committee Chair Cathy ...

In last week’s column, I told you how the 2024 General Election (early voting has started) could lead to healthier, smarter, and longer lives for all of us (see: ...

Pfizer slashed its production targets for its COVID ... more than 50 vaccines in clinical development and more than a dozen in late-stage trials, according to a regularly updated document from ...

Lots of news briefs (and some pictures) that didn't appear on our platforms but will likely be of interest. You may also see ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.